We are pleased to announce that a successful collaboration between glyXera and the University of Erlangen-Nuremberg has resulted in the publication of a research article inside the journal Frontiers in Immunology titled “Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo”.
Over the last decades, various recombinant monoclonal antibodies (mAbs) have been proven to be effective therapeutic agents against a diverse spectrum of diseases, such as cancer and inflammatory autoimmune disorders. The glycosylation of the fragment crystallizable (Fc) part of mAbs is described to have a strong impact on their effector function. While an afucosylated complex N-glycan attached to the mAb Fc increases antibody-dependent cellular cytotoxicity which is helpful in cancer therapy, a fully sialylated complex N-glycan can have an anti-inflammatory effect helping treat inflammatory autoimmune diseases.
The published article investigates to which extent a mAb glycosylation may change inside the patient after drug administration due to free sialyltransferase within the blood stream. A mouse model was established, injecting human intravenous immunoglobulin G (IgG) in B-cell deficient mice or in mice lacking free sialyltransferase 1. The IgG glycosylation was monitored over time by different methods, among which xCGE-LIF proved to be the method of choice, capable of handling the very limited quantities of mouse derived IgG.
The article is published open access and can be read in full here: https://www.frontiersin.org/articles/10.3389/fimmu.2019.03024 .
If you want to know more about glyXera’s high-performance xCGE-LIF technology and its applications in mAb and IgG N-Glycan analysis, please feel free to get in touch.